E
Eliav Barr
Researcher at Merck & Co.
Publications - 131
Citations - 22061
Eliav Barr is an academic researcher from Merck & Co.. The author has contributed to research in topics: Grazoprevir & Elbasvir. The author has an hindex of 58, co-authored 130 publications receiving 21129 citations. Previous affiliations of Eliav Barr include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more
TL;DR: The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women in this randomized, placebo-controlled, doubleblind trial.
Journal ArticleDOI
A controlled trial of a human papillomavirus type 16 vaccine.
Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Eliav Barr,Frances B. Alvarez,Lisa M. Chiacchierini,Kathrin U. Jansen +7 more
TL;DR: Administration of this HPV- 16 vaccine reduced the incidence of both HPV-16 infection and HPV-15-related cervical intraepithelial neoplasia, and immunizing HPV-14-negative women may eventually reduce the probability of cervical cancer.
Journal ArticleDOI
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Kevin A. Ault,Anna R. Giuliano,Cosette M. Wheeler,Laura A. Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven Eric Olsson,Margareta Steinwall,Darron R. Brown,Robert J. Kurman,Brigitte M. Ronnett,Mark H. Stoler,Alex Ferenczy,Diane M. Harper,Gretchen M. Tamms,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Kathrin U. Jansen,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +28 more
TL;DR: In this paper, a double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11).
Journal ArticleDOI
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano,Joel M. Palefsky,Stephen E. Goldstone,Edson D. Moreira,Mary E. Penny,Carlos Aranda,Eftyhia Vardas,Harald Moi,Heiko Jessen,Richard J. Hillman,Yen Hwa Chang,Daron G. Ferris,Danielle Rouleau,Janine T. Bryan,J. Brooke Marshall,Scott Vuocolo,Eliav Barr,David Radley,Richard M. Haupt,Dalya Guris +19 more
TL;DR: Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.